275. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2009;7:1053-1062.
276. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 2011;4:55-64.
277. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-799.
278. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. Am J Gastroenterol 2011;106:1264-1271.
279. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582.
280. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-1209.
281. Physicians’Desk Reference® (PDR®). PDR® web site <http://www.pdr.net>. Accessed 2010.
282. Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, et al. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother 2008;52:1759-1767.
283. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605.
284. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-2006.
285. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
286. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-596.
287. Heathcote EJ, Gane E, deMan R, Chan S, Sievert W, Mauss S, et al. Two year Tenofovir Disoproxil Fumarate (TDF) treatment and Adefovir Dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. [Abstract]. Hepatology 2008;48(Suppl 1):376A.
288. Marcellin P, Buti M, Krastev Z, Gurel S, Balabanska RI, Dusheiko G, et al. Two year Tenofovir Disoproxil Fumarate (TDF) treatment and Adefovir Dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102), Preliminary analysis. [Abstract]. Hepatology 2008;48(Suppl 1):370A.
289. Heathcote EJ, Gane EJ, deMan RA, Chan S, George J, Tsai N CS C,et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103) preliminary analysis. [Abstract]. Hepatology 2010;52 (Suppl 1). 556A.
290. Marcellin P, Buti M, Krastev Z, Gurel S, Di Bisceglie AM, Odin JA, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) tratment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. [Abstract]. Hepatology 2010;52(Suppl 1):555A.
291. Gordon SC, Marcellin P, Krastev Z, Horban A, Petersen J, Sperl J, et al. 4 year efficacy of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with high viral load (HBV DNA ≥9Log10 Copies/mL): preliminary analysis. [Abstract]. Hepatology 2010;52(Suppl 1):96A.
292. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil

<PAGE>111